Imdylltra
What Imdylltra is used for
Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Imdylltra
- Active substance
- tarlatamab
- Disease area
- Small Cell Lung Carcinoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX33
- Marketing authorisation holder
- Amgen Europe B.V.
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imdylltra used for?
Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
What is the active substance in Imdylltra?
Imdylltra contains tarlatamab.
Who makes Imdylltra?
The EU marketing authorisation holder is Amgen Europe B.V..
Is Imdylltra an orphan medicine?
Yes. Imdylltra is designated an orphan medicine in the EU, for a rare disease (Small Cell Lung Carcinoma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU